Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Philippines FDA Slashes Approval Timelines For Generic Drugs

Cuts Review From 120 To 45 Days As President Urges Lower Prices ‘Similar To India’

Executive Summary

The Philippines Food and Drug Administration is set to shorten the timeline for generic review and approval from 120 days to just 45 days, as part of efforts to register new generics and bring down prices.

You may also be interested in...



Stada And Alvotech Eye Launch Date For Ustekinumab After EU Approval

Stada has revealed details of exactly when in 2024 it plans to launch its Alvotech-partnered Uzpruvo ustekinumab biosimilar to Stelara, having just been granted a pan-European marketing authorization. At the same time, the German firm has also struck a distribution deal for prescription and consumer healthcare products with Zuellig in the Philippines.

Biocon Denies API Selloff Rumors As It Completes Biologics Integration

Biocon has rejected as “baseless and speculative” Indian media reports that it is considering divestment options for its API business. Meanwhile, the firm has celebrated completion of the integration of Viatris’s biosimilars business into its Biocon Biologics subsidiary.

Natco Furthers Chinese Interest With Xinjiang Pharmaceutical Alliance

With a strategy to expand its reach across Asian markets, Natco Pharma has struck a distribution agreement with Zhongchao Inc.’s Xinjiang Pharmaceutical to sell select products in China.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel